Primary central nervous system lymphoma

Genomic Testing Cooperative to Present Data at the American Society of Hematology Meeting on New Applications of its Proprietary Tests that Combine Transcriptome Data Obtained from Tissue or Liquid Biopsies with Machine Learning

Retrieved on: 
Tuesday, December 6, 2022
Biotechnology, Technology, Health, Pharmaceutical, Oncology, Research, Software, Artificial Intelligence, Genetics, Science, Clinical Trials, Prognosis, NGS, Diagnosis, GTC, Algorithm, Software, Degenerative disease, Transcriptome, Society, Health, Biomarker, Patient, DNA, Science, CFRNA, American Society of Hematology, LCA, Somatic mutation, Transplant, Nominal interest rate, Lymphoid neoplasms with plasmablastic differentiation, Nucleic acid thermodynamics, Artificial intelligence, Bone marrow, Cooperative, Machine learning, The, Lymphatic system, RNA, ASH, Primary central nervous system lymphoma, Birth control, Medical device

GTC continues to demonstrate the superior capabilities of their new cell-free (cfDNA) and cell-free RNA (cfRNA) liquid biopsy test called Liquid Trace.

Key Points: 
  • GTC continues to demonstrate the superior capabilities of their new cell-free (cfDNA) and cell-free RNA (cfRNA) liquid biopsy test called Liquid Trace.
  • Using cfRNA, GTC studies show that the cfRNA levels can be used in liquid immunoprofiling of hematologic neoplasms.
  • Combining this liquid immunophenotyping with machine learning algorithms report high reliability in the differential diagnosis between various types of lymphoid neoplasms/lymphoma.
  • The use of RNA profiling in tissue and liquid biopsies is opening new horizons in diagnostics, especially when combined with artificial intelligence.

10 Studies on Orelabrutinib Selected at the Upcoming 64th Annual Meeting of ASH

Retrieved on: 
Tuesday, November 8, 2022
Oncology, Health, FDA, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Food, Dexamethasone, MCD, MCL, FDA, CLL, BTK, SSE, NMPA, Cancer, Primary central nervous system lymphoma, Society, National Medical Products Administration, Lymphoma, Methotrexate, New Drug Application, Food and Drug Administration, Multiple sclerosis, DLBCL, Degenerative disease, PCNSL, B-cell lymphoma, HKEX, ASH, SLL, Neuromyelitis optica spectrum disorder, ITP, SLE, NMOSD, Breakthrough therapy, Fine chemical, Medical imaging, Pharmaceutical industry, Safety, Lenalidomide, Newly industrialized country, Patient, Rituximab

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that 10 studies on the BTK inhibitor orelabrutinib developed by InnoCare were selected at the 64th American Society of Hematology (ASH) Annual Meeting on December 10-13, 2022, which will be held online and offline in New Orleans, United States.

Key Points: 
  • InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that 10 studies on the BTK inhibitor orelabrutinib developed by InnoCare were selected at the 64th American Society of Hematology (ASH) Annual Meeting on December 10-13, 2022, which will be held online and offline in New Orleans, United States.
  • At the end of 2021, orelabrutinib was included into National Reimbursement Drug list to benefit more lymphoma patients.
  • The supplemental New Drug Applications of orelabrutinib for the treatment of R/R WM and R/R Marginal Zone Lymphoma were accepted in China.
  • Orelabrutinib was granted as Breakthrough Therapy Designation for the treatment of r/r MCL by U.S. Food and Drug Administration (FDA).

Cellectar Reports Financial Results for Third Quarter 2022 and Provides a Corporate Update

Retrieved on: 
Thursday, November 3, 2022
ORR, G&A, Company, Christian democracy, Research, Cancer, Part, Drug discovery, Lymphatic system, Neuroblastoma, GLOBE, FDA, Brain, Hand, Safety, Exchange, NCI, Multiple myeloma, COVID-19, Marketing, Immunotherapy, National Institute, Regulation, CNS, CEO, Primary central nervous system lymphoma, PIPE, Lymphoma, NASDAQ, Risk, State Administrative Expenses, Development, Sarcoma, R, WM, Security (finance), News, PDC, Survival, Patient, U.S. Securities and Exchange Commission, Cash, Pharmaceutical industry, Facebook, Nasdaq

FLORHAM PARK, N.J., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc.(NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today announced financial results for the third quarter ended September30, 2022 and provided a corporate update.

Key Points: 
  • FLORHAM PARK, N.J., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc.(NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today announced financial results for the third quarter ended September30, 2022 and provided a corporate update.
  • The mean overall survival at the time of data cutoff was 9.1 months, with median overall survival not yet reached.
  • The grant was awarded by the National Institute of Healths National Cancer Institute (NCI) based upon initial signals of efficacy.
  • These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements.

EQS-News: First CNS Lymphoma Patient Imaged with PentixaFor in Phase 2 Trial

Retrieved on: 
Friday, October 28, 2022
Gallium, Clinical trial, Radiopharmaceutical, Risk assessment, Department, Hematology, Primary central nervous system lymphoma, European Medicines Agency, Neoplasm, Patient, CNSL, Lymphoma, CXCR4, Publication, EMA, Pharmaceutical industry, Medical imaging, Yttrium, MD

The University Hospital Aalborg (Denmark) yesterday has imaged the first patient with Eckert and Zieglers Gallium (68Ga) boclatixafortide (PENTIXAFOR) in an international phase 2 trial.

Key Points: 
  • The University Hospital Aalborg (Denmark) yesterday has imaged the first patient with Eckert and Zieglers Gallium (68Ga) boclatixafortide (PENTIXAFOR) in an international phase 2 trial.
  • Code named PTF202, the clinical examination tries to measure the predictive potential of the CXCR4 receptor targeting radiotracer for the treatment of central nervous system lymphoma (CNSL).
  • If successful, PENTIXAFOR could change the way that chemotherapy in the future will be prescribed.
  • The European Medicine Agency (EMA) is currently reviewing a study design from Eckert & Ziegler for an even larger phase 3 trial with PENTIXAFOR which aims at patients suffering from various other forms of lymphoma.

Global Cancer Biomarkers Market to Surpass US$ 63,377.8 Million by 2030 - Coherent Market Insights

Retrieved on: 
Monday, July 4, 2022
Melanoma, Death, Patient, Primary central nervous system lymphoma, Pembrolizumab, Research, Breast cancer, Merck, DAWN, Biomarker, PerkinElmer, Growth, CNS, Cancer, Blood, Urine, Analysis, Company, Fluid mechanics, US, Thermo Fisher Scientific, EHA, Prevalence, World, Therapy, National Cancer Institute, CAGR, Nivolumab, University, World Health Organization, Ipilimumab, National, QIAGEN, Medical imaging, Pharmaceutical industry

SEATTLE, July 4, 2022 /PRNewswire/ -- According to Coherent Market Insights, the Global Cancer Biomarkers Market is estimated to be valued at US$ 21,643.9 million in 2022 and is expected to exhibit a CAGR of 14.4% during the forecast period (2022-2030).

Key Points: 
  • SEATTLE, July 4, 2022 /PRNewswire/ -- According to Coherent Market Insights, the Global Cancer Biomarkers Market is estimated to be valued at US$ 21,643.9 million in 2022 and is expected to exhibit a CAGR of 14.4% during the forecast period (2022-2030).
  • Key Trends and Analysis of the Global Cancer Biomarkers Market:
    Major players operating in market are focusing on carrying out research and development activities for developing biomarkers for early detection of cancer.
  • Global cancer biomarkers market is expected to exhibit a CAGR of 14.4% during the forecast period due to the increasing prevalence of cancer.
  • Market players are focusing on carrying out research and developments activities for developing protein biomarkers for the detection of cancer, which is expected to drive market growth.

U.S. FDA Approves Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi® for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy

Retrieved on: 
Saturday, June 25, 2022
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, FDA, DLBCL, Leukemia, Patient, Associate professor, Adult, Primary central nervous system lymphoma, Haematopoietic system, HIV disease progression rates, LLS, PFS, EFS, HSCT, Division, Progression-free survival, Disease, B-cell lymphoma, Bristol Myers Squibb, Life expectancy, CRS, Lymphatic system, Food, CAR, NYSE, University, Salvage therapy, Cytokine release syndrome, BMY, Anschutz Medical Campus, CD19, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Hope, Multimedia, Indolent lymphoma, Pharmaceutical industry, Lisocabtagene maraleucel, Hematology

With these two new indications, Breyanzi now has the broadest patient eligibility of any CAR T cell therapy in relapsed or refractory LBCL.

Key Points: 
  • With these two new indications, Breyanzi now has the broadest patient eligibility of any CAR T cell therapy in relapsed or refractory LBCL.
  • If left untreated, relapsed or refractory LBCL has a life expectancy of just three to four months.
  • In addition, the clinical profile of Breyanzi supported its use in a broad range of relapsed or refractory LBCL patients.
  • Bristol Myers Squibbs clinical development program for Breyanzi includes clinical studies in earlier lines of treatment for patients with relapsed or refractory LBCL and other types of lymphoma.

Four Independent Studies of Voraxaze® Published at European Hematology Conference 2022

Retrieved on: 
Thursday, June 9, 2022
Congress, AKI, Conference, THE, BODY, Toxicity, RISK, B-cell lymphoma, European Hematology Association, CNSL, MTX, AND, 2021 Essex County Council election, GLOBE, Patient, Risk, Glucarpidase, COVID-19, EHA, Trial of the century, CNS, Primary central nervous system lymphoma, Safety, Pharmaceutical industry, DLBCL

Vienna, June 09, 2022 (GLOBE NEWSWIRE) -- The European Hematology Association (EHA) Conference published four independent studies of Voraxaze (glucarpidase) by various investigators for inclusion in its June 2022 EHA Hybrid Congress abstract book and for publication in HemaSphere, EHAs peer-reviewed, open access journal.

Key Points: 
  • Vienna, June 09, 2022 (GLOBE NEWSWIRE) -- The European Hematology Association (EHA) Conference published four independent studies of Voraxaze (glucarpidase) by various investigators for inclusion in its June 2022 EHA Hybrid Congress abstract book and for publication in HemaSphere, EHAs peer-reviewed, open access journal.
  • Twenty outpatient treatments of HD-MTX with glucarpidase were administered to a total of 7 patients.
  • Some grade 1 and grade 2 adverse events attributable or possible attributable to Voraxaze were noted.
  • Voraxaze (glucarpidase) is currently approved in all members states of the European Union as well as Iceland, Liechtenstein, and Norway, where it is designated an orphan medicine.

Nurix Therapeutics Reports Dosing of First Patient in Phase 1 Clinical Trial of NX-5948, a Selective BTK Degrader, in Development for B-cell Leukemias and Lymphomas

Retrieved on: 
Tuesday, May 17, 2022
BTK, Lymphoid leukemia, Primary central nervous system lymphoma, Private Securities Litigation Reform Act, Enzyme, Nasdaq, Microglia, Patient, Goal, Solution, Therapy, Clinical trial, Society, COVID-19, United Kingdom, SAN, CNS, Intention, PCNSL, Forward-looking statement, Central nervous system, Safety, ASH, Protein, SEC, Cancer, Annual report, GLOBE, Pharmaceutical industry, Vaccine

Nurix is conducting the open-label, dose escalation and expansion trial at multiple centers in the United Kingdom.

Key Points: 
  • Nurix is conducting the open-label, dose escalation and expansion trial at multiple centers in the United Kingdom.
  • The trial is designed to evaluate the safety and tolerability of NX-5948 in adults with relapsed or refractory B-cell malignancies.
  • Brown, M.D., executive vice president of clinical development of Nurix.
  • NX-5948 has the potential to offer a differentiated clinical profile for patients with relapsed or refractory B cell malignancies.

Gossamer Bio Announces GB004 Topline Results from Phase 2 SHIFT-UC Study in Ulcerative Colitis and Provides Corporate Update

Retrieved on: 
Monday, April 25, 2022
Health, Other Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Annual report, Ulcerative colitis, STAR, Clinical trial, Nausea, GOSS, U.S. Securities and Exchange Commission, COVID-19, Security (finance), Somnolence, Bio, Research, Caregiver, PAH, Private Securities Litigation Reform Act, CNS, Entrepreneurship, Primary central nervous system lymphoma, Patient, Inflammation, Gossamer, Dizziness, Hypertensive emergency, Nasdaq, Company, UC, SEC, Safety, Industry, Therapy, Pharmaceutical industry, Medical imaging

I am proud of our teams efforts in trying to advance a new mechanism of action for patients with ulcerative colitis.

Key Points: 
  • I am proud of our teams efforts in trying to advance a new mechanism of action for patients with ulcerative colitis.
  • The Phase 2 SHIFT-UC Study (NCT04556383) enrolled 236 patients with mild-to-moderate active UC who were treatment nave to approved biologic therapies.
  • Topline results from ongoing Phase 2 TORREY Study are expected to be released in the fourth quarter of 2022.
  • ET today, Monday, April 25, to discuss its Phase 2 SHIFT-UC topline clinical trial results.

Autolus Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Progress

Retrieved on: 
Thursday, March 10, 2022
Multiple myeloma, Priority, CD19, BLA, Primary central nervous system lymphoma, Information, Retirement, Income tax, CRS, Depreciation, Toxicity, Therapy, Adult, Safety, Company, Corporate development, Director, Blackstone, Journal of Clinical Oncology, CAR, Collaboration, Journal, GLOBE, Patient, ALL, Neurotoxicity, MHRA, Clinical trial, PCR, Research, Workforce, Employment, EMA, CR, Hand, Sale, EFS, Senior advisor, Strategic management, ASH, Income, JCO, Nasdaq, Senior, CLL, Cytokine release syndrome, Lymphocytosis, Lymphoid leukemia, B-ALL, Board, Quarter, Human resources, COVID-19, Pharmaceutical industry, Medical device, Management, Cryptocurrency, Life insurance

LONDON, March 10, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc(Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced its operational and financial results for the fourth quarter and full year ended December 31, 2021.

Key Points: 
  • LONDON, March 10, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc(Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced its operational and financial results for the fourth quarter and full year ended December 31, 2021.
  • The latest data of obe-cel in relapsed/refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL) were presented by Autolus at ASH in December 2021.
  • Also in September 2021, Autolus announced the appointment of John H. Johnson as Non-Executive Chairman of the Board of Directors.
  • Dr. Lucinda Crabtree, Senior Vice President of Business Strategy & Planning at Autolus, will succeed Mr. Oakley as Autolus Chief Financial Officer.